Document is current
Any future updates will be listed below
-
Authors
Oknin-Vaisman, Avital
Panda, Deepanjan
Novak, Rostislav
Kheshaiboun, Ghazal https://orcid.org/0009-0002-4201-4470
Bitman-Lotan, Eliya
Gandhesiri, Satish
Kazi, Rubina
Pahor, Nikolett
von Heyl zu Herrnsheim, Viktoria https://orcid.org/0009-0005-0525-5218
Abu Ahmad, Yamen
Kamnesky, Guy
Mosler, Thorsten
Diefenbacher, Markus E. https://orcid.org/0000-0002-7402-7949
Brik, Ashraf https://orcid.org/0000-0001-8745-2250
Orian, Amir https://orcid.org/0000-0002-8521-1661
- License Information
-
More Information
Article History
Received: 11 April 2025
Revised: 20 April 2026
Accepted: 20 May 2026
First Online: 5 June 2026
Competing interests
: AOV, RN, DP, GK AB, and AO are listed as co-inventors in patent filings associated with the technologies described in this manuscript. Ao and AB. are co-inventors of intellectual property that is unrelated to this work (αRNF4 mAb). AB is a founder and consultant for Ub-Therapeutics™.
: All experiments involving human patients were performed with patient’s informed consents and according to Helsinki ethics committee permit: RBM-0536-22.
